PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8000259

[Virus inactivated plasma].

M Köhler·J U Wieding
View original source ↗Export metadata ↓

Abstract

Two different virus inactivated plasma preparations are available in Germany. Methylene blue ephotoxidized (MB) plasma is plasma from a single donation, which is photoxidized using 1 microM methylene blue and visible light (1 hour 60,000 Lux). Photochemical inactivation reduces HIV by at least 5 log10, but also fibrinogen is altered. To date, the clinical significance of this finding is still unclear, since prospective clinical studies are lacking. Solvent detergent (SD) plasma is manufactured from a pool of about 2000 plasma donations, and triton-X-100 and tri-n-butyl-phosphate (TNBP) are added for virus inactivation. HIV and hepatitis viruses are thus reduced by 5 to 6 log10. SD treatment reduces protein S and alpha-2-antiplasmin by about 40%. Clinical studies have already demonstrated, that SD plasma is comparable with untreated, native fresh frozen plasma in terms of efficacy.

Explore related subjects

Blood TransfusionBlood-Borne PathogensDetergentsHIVHepatitis VirusesHumansLightMethylene BluePlasmaRisk FactorsComparative StudyEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Köhler, J U Wieding. 1994. [Virus inactivated plasma].. https://pubmed.ncbi.nlm.nih.gov/8000259/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

The role of vertical transmission and health care-related factors in HIV infection of children: a community study in rural Uganda.

OBJECTIVES: To determine the probable route of transmission of HIV to children aged 12 years or younger in a rural area of Uganda from 1999 through 2000 and to examine associations between HIV infection and health care-related variables. METHODS: The HIV infections status for 6991 children was determined from 1 round of an ongoing population surveillance system, and the reported numbers of injections in the past year and blood transfusions were determined for 5922 of these children based on a medical questionnaire. Data from the surveillance system and from an additional survey were used to assess the potential for vertical infection from a mother to her child. RESULTS: The HIV prevalence among children was 0.4%. Of 23 definite and 4 probable cases of HIV infection in children, vertical transmission was not possible for 1 case, not likely for another case, and possibly not vertical for another case. The population-attributable fraction for vertical transmission was between 90% and 94%. Large numbers of injections in the past year and ever having a blood transfusion were only associated with HIV infection in children exposed to vertical transmission. CONCLUSIONS: Up to 10% of HIV infections in children in the study area were not attributable to vertical transmission, and thus were possibly attributable to iatrogenic transmission. Associations seen between health care-related variables and HIV were likely to be attributable to treatment for AIDS-related illness in children infected vertically.

Blood Transfusion↗
PubMed2007

Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation.

This paper describes the trends in haematopoietic stem cell transplantation (HSCT) activity for children in Europe over the last three decades. We analysed 31,713 consecutive paediatric HSCTs reported by the European Group for Blood and Marrow Transplantation (EBMT) centres between 1970 and 2002. Data were taken from the EBMT registry and were compared according to period and centre category (paediatric or combined). Since 1996, there has been a significant increase in the number of HSCTs performed exclusively by paediatric centres, as well as in the number of alternative donor HSCTs, and in the use of peripheral blood stem cells (P<0.0001). The number of allogeneic HSCTs (allo-HSCTs) for acute lymphoblastic leukaemia, acute myeloblastic leukaemia and chronic myeloid leukaemia remained stable, whereas it increased for myelodysplastic syndromes and lymphomas, and decreased significantly for non-malignant diseases (P<0.0001). Multivariate analysis showed that younger age, human leukocyte antigen genoidentical donors, HSCT performed after 1996 and transplant centres performing more than 10 allo-HSCT/year were all associated with decreased transplant-related mortality (TRM) (P<0.0001). The number of autologus HSCTs (auto-HSCTs) for acute leukaemia decreased significantly, whereas it increased for solid tumours (P<0.0001). Multivariate analysis showed that both auto-HSCT performed before 1996 and paediatric solid tumours (P<0.0001) had higher TRM. Indications for paediatric HSCT have changed considerably during the last seven years. These changes provide tools for decision making in health-care planning and counselling.

Blood Transfusion↗